Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00629876 · ClinicalTrials.gov registry record · Phase 1
A Safety and Tolerability Study of Peginesatide in Anemic Cancer Patients Receiving Cytotoxic Chemotherapy.
A Phase 1 study, sponsored by Takeda.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT00629876 is a Phase 1 study that was terminated before completion, run by Takeda. The registered enrollment target is 2 participants.
The verdict
NCT00629876, a Phase 1 study, was terminated before completion, sponsored by Takeda.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and tolerability of peginesatide used to treat anemia in subjects diagnosed with recurrent non-small cell lung cancer, breast cancer or prostate cancer and who also receiving a taxane chemotherapy.
Interventions
- DRUG Peginesatide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2008-01 |
| Est. Completion | 2008-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00629876
The ClinicalTrials.gov registry entry for NCT00629876 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Peginesatide is the first listed.
NCT00629876 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00629876 about?
NCT00629876 is a clinical study titled "A Safety and Tolerability Study of Peginesatide in Anemic Cancer Patients Receiving Cytotoxic Chemotherapy.". The purpose of this study is to determine the safety and tolerability of peginesatide used to treat anemia in subjects diagnosed with recurrent non-small cell lung cancer, breast cancer or prostate cancer and who also receiving a taxane chemotherapy.
What is the current status of trial NCT00629876?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2008-01. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00629876?
The interventions under investigation include: Peginesatide (DRUG).
Who is sponsoring clinical trial NCT00629876?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.